<SEC-DOCUMENT>0001372514-24-000027.txt : 20240325
<SEC-HEADER>0001372514-24-000027.hdr.sgml : 20240325
<ACCEPTANCE-DATETIME>20240325070336
ACCESSION NUMBER:		0001372514-24-000027
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240325
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240325
DATE AS OF CHANGE:		20240325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KIORA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001372514
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36672
		FILM NUMBER:		24776863

	BUSINESS ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024
		BUSINESS PHONE:		781-788-8869

	MAIL ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EYEGATE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20060811
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>kprx-20240325.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:dfa3da87-da1c-4496-bc77-0eace686fc1f,g:4e21952c-48e3-4326-b9d2-ee6bad64b11e,d:4b70f8c4d7ad4ff184b98e00a9035185-->
<html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>kprx-20240325</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001372514</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="kprx-20240325.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-25</xbrli:startDate><xbrli:endDate>2024-03-25</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4b70f8c4d7ad4ff184b98e00a9035185_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:8pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CURRENT REPORT PURSUANT</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported): </span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">March 25, 2024</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">KIORA PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation)</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36672</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">98-0443284</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">332 Encinitas Blvd.</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 102</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Encinitas</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">CA</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">92024</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">858</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">224-9600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">KPRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" id="f-20">NASDAQ</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4b70f8c4d7ad4ff184b98e00a9035185_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 2.02.&#160;&#160;&#160;&#160;Results of Operations and Financial Conditions.</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 25, 2024, Kiora Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release announcing financial results for the year ended December 31, 2023 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. This information will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates them by reference. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i4b70f8c4d7ad4ff184b98e00a9035185_10"></div><div style="-sec-extract:summary;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:10pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.74pt"> Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit&#160;<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex991-pressreleasedecember.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex991-pressreleasedecember.htm">Press Release of Kiora Pharmaceuticals, Inc., dated as of March 25, 2024</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4b70f8c4d7ad4ff184b98e00a9035185_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.841%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">KIORA PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Melissa Tosca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melissa Tosca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President of Finance</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal financial and accounting officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March 25, 2024</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-pressreleasedecember.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i1485398a5b8643eeae2847842fd0fa82_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Kiora Pharmaceuticals Reports 2023 Results&#59; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases&#59; Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encinitas, California -- March 25, 2024 - Kiora Pharmaceuticals, Inc. (NASDAQ&#58; KPRX) (&#34;Kiora&#34; or the &#34;Company&#34;) today announced its 2023 financial results and provided an update on its retinal disease development pipeline. The Company&#8217;s major initiatives planned for 2024 are to initiate Phase 2 clinical development of KIO-301, a small molecule photoswitch, for the treatment of inherited retinal diseases, starting with retinitis pigmentosa (RP)&#59; and further development of KIO-104, an intravitreal, anti-inflammatory for treatment of non-infectious uveitis. The $16 million upfront payment from Kiora&#8217;s development and commercialization partnership with </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Th&#233;a Open Innovation (TOI)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for KIO-301 and its $15 million private placement are expected to be sufficient to fund the Company through 2026, excluding any potential partnership milestones or warrant exercises. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Our greatest priorities this year are to advance KIO-301 and KIO-104 to assess their further potential to benefit patients,&#8221; said Brian M. Strem, Ph.D., chief executive officer of Kiora. &#8220;Both products are clinically validated drug candidates based on proprietary and innovative small molecules targeting rare retinal diseases with large unmet needs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><img alt="picture1.jpg" src="picture1.jpg" style="height:192px;margin-bottom:5pt;vertical-align:text-bottom;width:565px"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;KIO-301 could potentially become the first vision restoring option for patients with inherited retinal degenerative diseases like RP. Ongoing development will be collaboratively guided and fully funded by our partner, TOI. Should KIO-301 gain marketing authorization, it would provide Kiora with meaningful commercial milestones and royalties up to the low 20&#8217;s with a partner who has a proven track-record of leadership in the eye space. Working with TOI, we are finalizing details of the randomized, double-masked, controlled, dose-ascending Phase 2 trial in RP and look forward to providing more specifics on expected enrollment and results timelines. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;The balance sheet provides us financial ability to fund the further development of KIO-104 for the treatment of posterior non-infectious uveitis. Because non-infectious uveitis can be sight threatening, there is a strong market appetite for new, steroid sparing therapeutic approaches. The active compound in KIO-104 is a highly potent, disease modifying anti-inflammatory agent belonging to a class of drugs helping hundreds of thousands of patients with systemic autoimmune diseases including multiple sclerosis and rheumatoid arthritis. By delivering KIO-104 directly to the eye, we believe we can reduce the negative effects of retinal inflammation without </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the associated potential side effects of systemic anti-inflammatory drugs or chronic steroid exposure. Beyond non-infectious uveitis, the mechanism of action of KIO-104 could apply to other retinal conditions, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such as p</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">roliferative vitreoretinopathy (PVR), a complication following retinal detachment repair, where nonclinical work is ongoing.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Orphan indications involve efficient, cost-effective paths to market,&#8221; added Melissa Tosca, EVP Finance. &#8220;For 2024, we expect to increase our R&#38;D spend, with expenses for KIO-301 offset by quarterly reimbursement from TOI. Further, we anticipate G&#38;A expenses to remain relatively flat for the year. We believe this balances our </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">desire to accelerate meaningful development while maintaining a strong cash position expected to fund operations through 2026.&#8221; </font></div><div style="text-align:center"><img alt="picture2.jpg" src="picture2.jpg" style="height:182px;margin-bottom:5pt;vertical-align:text-bottom;width:536px"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Achieved and Upcoming Milestones&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notable milestones that Kiora achieved in 2023 and year-to-date 2024 include the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KIO-301</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Entered </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a strategic partnership granting TOI exclusive worldwide development and commercialization rights, excluding Asia, to KIO-301 for the treatment of retinal degenerative diseases. Under the terms of the deal, Kiora received an upfront payment of $16 million and is eligible to receive up to an additional $285 million in development, regulatory, and commercial milestones&#59; tiered royalties of up to low 20&#8217;s on net sales&#59; and reimbursement of KIO-301 research and development expenses.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Completed enrollment and reported topline results from ABACUS-1 study. Results demonstrated KIO-301 was safe and tolerable and demonstrated improvements consistent across multiple measures, including improved visual field, visual acuity, and functional vision (navigating in real-world simulations). In addition, functional MRI measures showed reactivation of the specific regions of the brain responsible for vision.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Held a Type B, pre-IND meeting with the US FDA regarding Kiora&#8217;s proposed clinical development plans and received feedback on trial design, including approvable endpoints, details for the control group, and outstanding non-clinical requirements, all consistent with Kiora&#8217;s current plans and timelines. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KIO-100 Family (KIO-104, KIO-101)</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The publication of results from Phase 1 double-masked study of KIO-101 in the medical journal </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmaceutics</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, documenting </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a 12-day treatment of KIO-101 topically at multiple doses was well tolerated in healthy volunteers and patients with inflammation of the eye. There was a significant decrease in conjunctival hyperemia in the treatment group compared to the placebo group.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Granted US and European patents covering local ocular delivery of the KIO-100 family of non-steroidal, anti-inflammatory small molecules.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kiora anticipates achieving the following clinical and regulatory milestones&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KIO-301</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Report additional ABACUS-1 data, including quantitative functional MRI measures showing reactivated brain activity in the visual cortex in a time-dependent manner.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Complete comprehensive design, under the joint Kiora-TOI steering committee, of a randomized, controlled, multicenter, double-masked, dose-ascending Phase 2 study of KIO-301 in retinitis pigmentosa with initiation expected as early as the fourth quarter of 2024. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Pursue Orphan Drug Designations for KIO-301 for choroideremia and Stargardt disease in the US and EU.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KIO-104</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Initiate supportive non-clinical research to inform and optimize Phase 2 and registration studies in 2024.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Plan a multicenter, randomized, double-masked, dose-ascending Phase 2 study of KIO-104 for the treatment of non-infectious uveitis.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Perform additional pre-clinical proof-of-concept studies of KIO-104 in proliferative vitreoretinopathy, a rare but serious complication of retinal reattachment procedures beginning in 2024. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Results</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kiora ended the year with $2.5 million in cash and cash equivalents and $2.0 million in tax receivables. In February of 2024, Kiora received an additional $16 million for an upfront payment from TOI and raised $13.8 million in net proceeds from a private placement offering. The Company&#8217;s cash and cash equivalents as of March 24, 2024, exceeds $30 million and the Company believes this will fund operations through 2026.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, research and development expenses were $4.0 million, net of $1.7 million in offsetting tax credits, compared to $3.5 million, net of $1.5 million in offsetting tax credits, for 2022. Research and development expenses for the fourth quarter of 2023 were $1.1 million, net of $0.5 million in offsetting tax credits, compared to $0.8 million, net of $0.4 million in offsetting tax credits for the fourth quarter of 2022. The increase in R&#38;D in 2023 was primarily due to greater investment in clinical trial-related activities for KIO-301 and personnel-related expenses for the R&#38;D team. Kiora anticipates R&#38;D expenses will increase as it begins planning and enrollment of patients in Phase 2 clinical trials, with trial-related expenses for KIO-301 offset by reimbursement from TOI. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses for 2023 were $4.7 million compared to $8.3 million for 2022. General and administrative expenses for the fourth quarter of 2023 were $0.9 million, compared to $2.8 million in the fourth quarter of 2022. The reduction in general and administrative expenses for the full year and fourth quarter of 2023 were primarily related to lower professional service fees, driven by reduced external accounting and auditing services. Kiora expects that general and administrative expenses will remain relatively consistent for the near future.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss was $12.5 million for 2023 compared to $13.6 million for 2022. Net loss was $2.3 million for the fourth quarter of 2023 compared to $2.5 million for the fourth quarter of 2022. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Kiora Pharmaceuticals</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and&#47;or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase. In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and&#47;or subscribe to email alerts.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the statements in this press release are &#34;forward-looking&#34; and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These &#34;forward-looking&#34; statements include statements relating to, among other things, Kiora's ability to execute on development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-104, KIO-301, KIO-201 and KIO-101, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all, the sufficiency of existing cash on hand to fund operations for specific periods, the ability to timely complete planned initiatives for 2024, including phase 2 </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical development of KIO-301 and KIO-104, the potential for KIO-301 to be the first treatment options for patients with inherited degenerative diseases like RP, Kiora&#8217;s plans to further fund development of KIO-104, the potential for KIO-104 to reduce inflammation, the timing of topline results from a Phase 2b trial of KIO-104, the potential for KIO-104 to apply to other retinal inflammatory diseases, and expected trends for research and development and general and administrative spending in 2024. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to satisfy the closing conditions related to the offering ,the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading &#34;Risk Factors&#34; contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 25, 2024 or described in Kiora's other public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contact Information&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors&#64;kiorapharma.com</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>kprx-20240325.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:dfa3da87-da1c-4496-bc77-0eace686fc1f,g:4e21952c-48e3-4326-b9d2-ee6bad64b11e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:kprx="http://www.eyegatepharma.com/20240325" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.eyegatepharma.com/20240325">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20240325_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20240325_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.eyegatepharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>kprx-20240325_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:dfa3da87-da1c-4496-bc77-0eace686fc1f,g:4e21952c-48e3-4326-b9d2-ee6bad64b11e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_16357d48-e92a-4af1-8c35-4592e98dbeb8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ced3b310-c96c-4a11-99b5-b8a6f0c546fb_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_4c1b31ae-97ee-40a0-95f0-cb498b4849c9_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2d830fa8-98d9-4067-9440-82c997309174_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ae0875b8-0915-4c97-b7b8-7d95b5c59301_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c960a5d3-5541-49f1-90f4-e57db2287823_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_49c491bf-717d-4efb-97f7-a12cdcdf1f8e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_87fe94b8-87d3-4b1d-a8e6-3d564d22b37a_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_be6a2b7f-98fb-400c-b581-48b6e880ed72_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b50709a1-9cd1-468d-9849-8c03e88e95cf_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_380c9f11-4f83-4f93-81c4-ebf168931441_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_88e2229e-d6d8-4498-9561-83c1b811dc2e_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ee9a0d58-7daf-4f96-88b5-8ca02b11c88c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_53b7f07e-48d7-41b5-9ff8-daf4d28b8542_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_657039e0-9894-4c4d-a66c-33409a05b0b4_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f325f417-79b9-4c5b-bf1f-48a696fca8cc_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8472b23c-a658-4e3e-b058-59630b2e3de0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3b1576ad-f0c6-476b-bce8-744c568a2f45_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_364e3802-fbfc-4c34-96ac-57b74547a412_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e3c947ae-67c2-44a7-bfc3-7115108a6346_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_fa2127d9-ef9d-4804-b885-94cfd2b7967e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_ad0ac032-4e70-4ffa-ae21-146757d2b6df_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c30d4659-ca49-408e-907e-fdcda783afcc_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>kprx-20240325_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:dfa3da87-da1c-4496-bc77-0eace686fc1f,g:4e21952c-48e3-4326-b9d2-ee6bad64b11e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/Cover" xlink:type="simple" xlink:href="kprx-20240325.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a796c18a-64ce-4d42-b469-782af62445f6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_DocumentType_a796c18a-64ce-4d42-b469-782af62445f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a148b5fe-8eca-40ee-9c0e-251e38be8370" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_DocumentPeriodEndDate_a148b5fe-8eca-40ee-9c0e-251e38be8370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_dbddcabc-2a67-4e50-a67a-d58bac98b19b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_EntityRegistrantName_dbddcabc-2a67-4e50-a67a-d58bac98b19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_10abd30a-befb-40ba-bceb-e08a34386991" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_EntityIncorporationStateCountryCode_10abd30a-befb-40ba-bceb-e08a34386991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_8c10637e-aabb-4d4c-aed3-5b5acf87a61c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_EntityTaxIdentificationNumber_8c10637e-aabb-4d4c-aed3-5b5acf87a61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c358f2c4-b4ff-487d-ad37-929857d0fdfc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_EntityFileNumber_c358f2c4-b4ff-487d-ad37-929857d0fdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3e4ce094-06c4-4bdc-8013-4b8362a397e3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_EntityAddressAddressLine1_3e4ce094-06c4-4bdc-8013-4b8362a397e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_e55089ac-ae3e-4570-82bb-bf5f0c8ff75c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_EntityAddressAddressLine2_e55089ac-ae3e-4570-82bb-bf5f0c8ff75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2c8fb045-a3ab-4e00-9aa3-775a8cf6505c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_EntityAddressCityOrTown_2c8fb045-a3ab-4e00-9aa3-775a8cf6505c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f715659a-885a-4413-a9ab-7a02aaf261f5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_EntityAddressStateOrProvince_f715659a-885a-4413-a9ab-7a02aaf261f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_03355f1c-251f-4f48-8a8c-9ad2bc857808" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_EntityAddressPostalZipCode_03355f1c-251f-4f48-8a8c-9ad2bc857808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f8113361-4aa5-42c1-b356-172a67393e13" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_CityAreaCode_f8113361-4aa5-42c1-b356-172a67393e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8975ce4d-775f-405a-9a96-83dd5317819a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_LocalPhoneNumber_8975ce4d-775f-405a-9a96-83dd5317819a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_f72b8b11-2482-4708-b129-2c47d1646693" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_WrittenCommunications_f72b8b11-2482-4708-b129-2c47d1646693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_ee677cb6-c69b-40be-a197-6695bd63ab9b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_SolicitingMaterial_ee677cb6-c69b-40be-a197-6695bd63ab9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_0d507b55-b0b1-4a95-a0b4-6e9c7d19d610" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_PreCommencementTenderOffer_0d507b55-b0b1-4a95-a0b4-6e9c7d19d610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_76f9d367-05a6-4ae2-a1a0-793b3f99798e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_76f9d367-05a6-4ae2-a1a0-793b3f99798e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_673df923-2e2e-46ad-a81a-f978bb712299" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_Security12bTitle_673df923-2e2e-46ad-a81a-f978bb712299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_11e1480d-40d1-4321-8ffc-248b2ee6c62b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_TradingSymbol_11e1480d-40d1-4321-8ffc-248b2ee6c62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c963ef67-7245-49f4-9e02-7d19e285a7fe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_SecurityExchangeName_c963ef67-7245-49f4-9e02-7d19e285a7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_987b5127-0369-4052-aac6-c59be9bea3c0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_EntityEmergingGrowthCompany_987b5127-0369-4052-aac6-c59be9bea3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3428bdd2-07ad-457c-8810-e786a035ef70" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_EntityCentralIndexKey_3428bdd2-07ad-457c-8810-e786a035ef70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e3df4a36-2f40-437d-8310-59e6f552b77f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34fee1d2-f4ad-44fc-ba83-d4566582bb59" xlink:to="loc_dei_AmendmentFlag_e3df4a36-2f40-437d-8310-59e6f552b77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>picture1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 picture1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $$ OX# 2(  A$! Q$!_\0
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M1HF[NX4445F4%%%% !1110!GZ]KVG>%]'NM5U:\BL-/M5WS7$QPJC.!]220
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M /[2K>1];?\ #2W@C_GXO?\ P$>C_AI;P1_S\7O_ ("/7R311_8^&\_O_P"
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M /[2K>1];?\ #2W@C_GXO?\ P$>C_AI;P1_S\7O_ ("/7R311_8^&\_O_P"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#VW]E+_D<-;_Z\%_\ 1@KZ>KYA_92_Y'#6_P#KP7_T8*^GJ^$S
M;_>I>B_(^IR_^ OF%?(OQ(^&WB+4_'_B"[MK#S+>:\=XV\U!D'O@FOKJO-=<
M_P"0S>_]=36> Q$L/.4H]4:XJC&M%*1\V?\ "J/%/_0-'_?Y/\:/^%4>*?\
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M'_?Y/\:/^%4>*?\ H&C_ +_)_C7T+@^E R>!R:/[2K=E^/\ F'U*GW9\]?\
M"J/%/_0-'_?Y/\:/^%4>*?\ H&C_ +_)_C7T,49>JD?A24?VE6[+\?\ ,/J5
M/NSYZ_X51XI_Z!H_[_)_C1_PJCQ3_P! T?\ ?Y/\:^A:*/[2K=E^/^8?4J?=
MGSU_PJCQ3_T#1_W^3_&C_A5'BG_H&C_O\G^-?0M%']I5NR_'_,/J5/NSYZ_X
M51XI_P"@:/\ O\G^-'_"J/%/_0-'_?Y/\:^A:*/[2K=E^/\ F'U*GW9\]?\
M"J/%/_0-'_?Y/\:/^%4>*?\ H&C_ +_)_C7T+11_:5;LOQ_S#ZE3[L^>O^%4
M>*?^@:/^_P G^-'_  JCQ3_T#1_W^3_&OH6BC^TJW9?C_F'U*GW9\]?\*H\4
M_P#0-'_?Y/\ &C_A5'BG_H&C_O\ )_C7L7C'XC^%/A["DOB?Q'IN@I)RGVZY
M6-F]PO4C\*Y'_AJ3X0?]%'T#_P "?_K5:S#$/517W,7U.DMV<7_PJCQ3_P!
MT?\ ?Y/\:/\ A5'BG_H&C_O\G^-=I_PU)\(/^BCZ!_X$_P#UJ/\ AJ3X0?\
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M^%4>*?\ H&C_ +_)_C7:?\-2?"#_ **/H'_@3_\ 6H_X:D^$'_11] _\"?\
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M+'N_W0>3^ H695GHDOQ_S#ZE2[L\7_X51XI_Z!H_[_)_C1_PJCQ3_P! T?\
M?Y/\:[3_ (:D^$'_ $4?0/\ P)_^M1_PU)\(/^BCZ!_X$_\ UJOZ_B/Y/P9/
MU2C_ #?D<7_PJCQ3_P! T?\ ?Y/\:/\ A5'BG_H&C_O\G^-=I_PU)\(/^BCZ
M!_X$_P#UJ/\ AJ3X0?\ 11] _P# G_ZU'U_$?R?@P^J4?YOR.+_X51XI_P"@
M:/\ O\G^-'_"J/%/_0-'_?Y/\:]2\(_&CP#X]OOL7AWQCHVL7G:WMKI3(?HI
MP3^%=G4/,:RWBOQ_S&L'2>S9\]?\*H\4_P#0-'_?Y/\ &C_A5'BG_H&C_O\
M)_C7T+12_M*MV7X_YC^I4^[/GK_A5'BG_H&C_O\ )_C1_P *H\4_] T?]_D_
MQKZ%HH_M*MV7X_YA]2I]V?/7_"J/%/\ T#1_W^3_ !H_X51XI_Z!H_[_ "?X
MU]"T4?VE6[+\?\P^I4^[/GK_ (51XI_Z!H_[_)_C1_PJCQ3_ - T?]_D_P :
M^A:*/[2K=E^/^8?4J?=GSU_PJCQ3_P! T?\ ?Y/\:/\ A5'BG_H&C_O\G^-?
M0M%']I5NR_'_ ##ZE3[L^>O^%4>*?^@:/^_R?XT?\*H\4_\ 0-'_ '^3_&OH
M6BC^TJW9?C_F'U*GW9\]?\*H\4_] T?]_D_QH_X51XI_Z!H_[_)_C7T+11_:
M5;LOQ_S#ZE3[L^>O^%4>*?\ H&C_ +_)_C1_PJCQ3_T#1_W^3_&OH6BC^TJW
M9?C_ )A]2I]V?/7_  JCQ3_T#1_W^3_&C_A5'BG_ *!H_P"_R?XU]"T4?VE6
M[+\?\P^I4^[/GK_A5'BG_H&C_O\ )_C1_P *H\4_] T?]_D_QKZ%HH_M*MV7
MX_YA]2I]V?/7_"J/%/\ T#1_W^3_ !H_X51XI_Z!H_[_ "?XU]"T4?VE6[+\
M?\P^I4^[/GK_ (51XI_Z!H_[_)_C1_PJCQ3_ - T?]_D_P :^A:*/[2K=E^/
M^8?4J?=GSU_PJCQ3_P! T?\ ?Y/\:/\ A5'BG_H&C_O\G^-?0M%']I5NR_'_
M ##ZE3[L^>O^%4>*?^@:/^_R?XT?\*H\4_\ 0-'_ '^3_&OH6BC^TJW9?C_F
M'U*GW9\]?\*H\4_] T?]_D_QH_X51XI_Z!H_[_)_C7T+11_:5;LOQ_S#ZE3[
MLY3]F_P7K'AGQ1JT^I6GV>*2S5%;S%;)W@XX-?0=<7X&_P"0A<_]<A_.NTKY
M_&595JSG+<]?#TU2IJ,0KS77/^0S>_\ 74UZ57FNN?\ (9O?^NIK/#[LJKL4
M:***[CF"BBB@ HHHH **** "BBB@#SWX_P!U<V?PAUZ6TDDBN,VZJT,S0L=U
MQ&I4.O*Y!(R.QKS/3OB5XA\)W5[I.GV?V.XN=7NX1I.I78NO['6"!&$7FS2Q
MAQ.295;?@(3M!(('NOB_6K'P[X=NK_4H#=VL91?LRH'::1G58T53P6+E<9^M
M85MXV\&>);+Q;=RBUDB\/7,EMK)O;9<Q/ I;+;A\R@9VM]0*VB_=M:YG):[G
MF&I^,O%&I:EKOVW5[6VM5U'P\O\ 8L.[S(X[AHO,\JXCF&5#.<L 5? !X.*C
MUWXO>(K[P9/-J2V+0:G87EU NG^=;2VYMK^*#!D$F3O5\G&W!&.0:]F\.:QX
M=\9:'IOB.SAM6MK^UAFAEN84241$[H@P/*\C(!Z$<<T:7K7A77M/\^SGTNXL
MTGEL@2(PHD$A#Q@'U=<X[D \T^9=4*WF>/MXQ\41ZZCW6N6.IBW\8ZC90V+J
MUH8A';RO"))%EQY7RCY70CJW88V]4\?:CXE_9Y\?:E/<&WUS3]/O(9FM(_LY
MMYA ' 1UD<-C<,2(_(P>#D5W5QXL\*1ZK=01BUO-4348K"YBMH$DG6X=0 7'
M4@*XRW8$BMR"/1H=/N+* :<EA"3%-;Q^6(DSU5E' SZ'K0Y;:#MYGBEK!KWA
M/6_#MZ]O<:=HFI7UNEGI%UJTMPRRI8W,DLK.&.%D(C'EDL/E+8!Q4GA3XS>*
M_%ECHDEO+H:?VOJ=K813^5O:$RP2R2;HEF)PC(%5F*[QDX%>U75OIFN:6XG%
MM=Z>T;@R;E9%0J58AA]WY2PR#P,UP?PFA\"7_A]O%/AUYIK5L6GVW6)&,L"P
M$A$!D^XH#DKZAP<\T<R:NT+EL]&</!\?O%$>AVEU<:?IUQ/JEC:W<'V9"B67
MFWC6SF0O( ZC 8$L@RP4G'-7K[XQ^,+6RU"9K;1[=M)T6;6+E& G-T([KR@J
MF*9EB+)R?F<JW'->P[-$4);XTT":/R$A_=_O(R2=@7NI.3CIUIT-IHT?G6<4
M.GKY,/ERVZI&/+BZ[67LG?!XI<T?Y1\K[GD&E_$CQ';ZWJNGSZYI@-[XIGTV
M"YOK;$>E0+;B9-X\T;M^-J@E1G<<GI3M&^.VIW%WHMQJR:?I>CWEO(//A0SB
M69#/ER XDBB981(C;&# GYA@9]"UGQ)X-LYI[:]ETN>>[LVOG@V1R&ZAB(&?
M1R#@*#SGI4NJZ]H6E:(?$,EC&\T&G?:TMQ#&MZ+;:&950_, %SE>G!%.Z_E"
MS[F#\(/B1=^/YO$,%TT-PNFR6QANX+9K<2I-%Y@S&SL1C& <\@C(!XKT:J6D
MVNGV]G%)IEO;06LR*Z&UB5%92,J> .,']:NUE)IO0M;:A1114C"O/?C]\5%^
M"_PEU[Q6(UGN[6-8K.&3[KW$AVQ@^P)R?937H5>#_MO>"[[QM^SGK\.G1//=
M:?-!J?DQC+/'$V7 '<A23^!K2FDYI/8F3:BVC\N/%'BC5_&VOW>MZ]J$VJZM
M=.7FNKAMS$GL/[JCL!P*RZ0$, 1R#2U]">.%%%% @HHHH **** "BBB@!&4,
M,$9'O7U5^PC\?=5\&_$73_ FHWDESX7UR0P6\,K%A9W)!*,F>BL1M*CC)!KY
M6KU[]DGP;?>-?VA?!L%G$S1Z?>+J5U(!Q%#"=Y8^F2%7ZM655*4&I&E-M25C
M]=:_/K_@H'\?M5NO%\GPTT:\DLM(L(HY-5,#E6NIG7<(V(YV*I4[>Y//2OT%
M8Y8FORN_;L\&WWA;]HK7;^XC;[%KJ1:A:3$?*X\M4=0?560Y^HKR\*DZFIWU
MVU#0^?%4*,  #T%+117LGF!1110 4444 %%%% !1110!;T?5[[P_JMMJ>EWD
MVG:E;.)(+JV<I)&PZ$$5^M?[+/QEF^.'P@T_7;\(NM6TC6.H^6,*TR8_> =@
MZD-CU)K\B:_3?_@GKX.OO#'P'DU"^B:'^W=1DOK>-Q@^2%6-7^C;21[5Q8M+
MDN]SJP[?-8]Q^*WC^V^%GPY\0^++J/SH]*M&G6'./,DX6-,^[%1^-?CMX\\>
MZ]\3O%%WXA\27\FHZG<N6+.?DB7LD:]%4= !7ZO_ +4W@V^\??L_^,]'TR-I
MK]K07$,*=9#$ZR%0.Y(0@>]?D"#G_P"O48-+E;ZE8ANZ70****] XPHHHH =
M#+);W$4\,CPSQ,'CEC8JZ,.A!'(/TK]1/V(/CMJ/QD^&]W8Z_.;KQ#X?E2WF
MNF^]<PL,QR-_M<%2>^ :_+FOO[_@F?X-OK#PWXR\43QM%9:E-#96I88$OE;F
M=A[ N!]0:Y,4DZ=V=-!OGLC[5HHHKQ3T@HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .D\#?\A"Y_P"N
M0_G7:5Q?@;_D(7/_ %R'\Z[2O.K_ !G73^$*\UUS_D,WO_74UZ57FNN?\AF]
M_P"NIJ\/NR:NQ1HHHKN.8**** "BBB@ HHHH **** .3^*&EWFJ>$\Z?;M>7
MEC?6FH):I]Z80SH[(,]RH./<"N-B^ _VS5)[Z\U#R(;K5+NZU"QMQF/4[9K@
MSVL4Q(&#&YR<9R"R]*]>HJU)I61+BGJSPFW^"_BG3]%@TR)]*GCN+71XKN9[
MAU,+65R9'"+L.\.IX)*X(Y%0:U\$O$]QX0O/#>GVOAVVM9KG4Y/MFU?.;[1(
MSPO\T+;-H8JP7YN%VN*]]HJO:2%R(\7D^"NIR:AJ#K#I44EQKNGZPFJH?])5
M8X$CG3[F<[D+ [OFW<XK)'P#UNYT%-.DCT>S^SZ9:Z9(UO(S#53'>PSM<3C8
M,-MB8 '<=TC9;%>_44>TD'(CS&Z^&>K1>#?&^@:7/::;'X@U:66!H"46TLIA
M&LNU0N!)M63"@8RP.>M<9X^^%NL>%K6Z&EW%QK.C7M_IUV_G0H\MG- &C9S%
M'"4:,Q+&O^K?Y@"5/4?0- )'(X-)5&@<4?/>A_!.[UCPS/<6VBVF@S2:=86N
MGP7S[I[=[>]DE>7<$!3S%8,, 'YL$#%:EU\#]3O6EM;FWTZ6VC?5'DOX;MX;
MS5UNV)2*=@F8PF1SE^8UP .*]PHI^TD'(CPV/X*:Y-';-J%KH.H3MHFI:0QD
M1%:W\Y]UN^5A"R,N,,P5#DDBK5K\.]>\':7XBD&CZ;XDN;NQ407GF$WL,@LE
MMQ;QADY3>I(;>ORNV1FO:**/:,.5&=X;TMM#\-Z3IKN)'L[.&V9UZ$HBJ3^E
M:-%%9%A1110 4A 8$$!@1@@C((]#2T4 ?)/Q:_X)W^%O&FM7&K>$]9?PA-<.
M9);!H//M-Q.24 (9.?X0<>F*\Y_X=AZU_P!%$TW_ ,%<O_QROORBNE8BK%6N
M8NC!N]CX#_X=AZU_T433?_!7+_\ '*/^'8>M?]%$TW_P5R__ !ROORBG]:J]
MQ>QI]CX#_P"'8>M?]%$TW_P5R_\ QRC_ (=AZU_T433?_!7+_P#'*^_**/K5
M7N'L:?8^ _\ AV'K7_11--_\%<O_ ,<H_P"'8>M?]%$TW_P5R_\ QROORBCZ
MU5[A[&GV/@/_ (=AZU_T433?_!7+_P#'*/\ AV'K7_11--_\%<O_ ,<K[\HH
M^M5>X>QI]CX*L_\ @F)J'VA/MGQ#M/L^?G^SZ8^_'MN?&:^J_@A^S]X3^ >A
MS6/AZ"2:]NL&\U2[(:XN2.@)'"J.RCCZUZ516<ZU2HK29<:<8NZ05POQ@^"_
MA?XX>%_[%\3VC2+&QDM;R!MEQ:R$8W(WOW!X/>NZHK)-Q=T6TFK,^#M2_P""
M8EW]LD_LWXAVXM,_(+S3&,F/<J^,U4_X=AZU_P!%$TW_ ,%<O_QROORBNGZS
M5[F/L:?8^ _^'8>M?]%$TW_P5R__ !RC_AV'K7_11--_\%<O_P <K[\HH^M5
M>X>QI]CX#_X=AZU_T433?_!7+_\ '*/^'8>M?]%$TW_P5R__ !ROORBCZU5[
MA[&GV/@/_AV'K7_11--_\%<O_P <H_X=AZU_T433?_!7+_\ '*^_**/K57N'
ML:?8^ _^'8>M?]%$TW_P5R__ !RC_AV)K7_10]-_\%<O_P <K[\HH^M5>X>Q
MI]CXY^&O_!-WP[X?U>&_\8>(I/$\4+!UTZU@-M!(1_ST)8L1[#&:^PK>WAL[
M>*WMXD@MX4$<<,2A410,!0!T ':I**QG4E4UDS2,(P^% "0<C@U\M?&O]@3P
MI\2]<N==\.ZD_@_5;IS)<0QP"6SE<\EPF04)ZG:<$]J^I:*4*DJ;O%CE%25F
M? G_  [#UK_HHFF_^"N7_P".4G_#L/6O^BB:;_X*Y?\ XY7WY16_UJKW,O8T
M^Q\!_P##L/6O^BB:;_X*Y?\ XY1_P[#UK_HHFF_^"N7_ ..5]^44?6JO</8T
M^Q\3>"_^"9^FV.J13^*_&4FK6,;!FL],M3;^;_LL[,Q ^G-?9/A_P_IOA31+
M+1]'LH=.TNRB$-O:P+A(U'8?X]2:T**RG4G4^)FD81A\*"BBBLBPHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** .D\#?\A"Y_ZY#^==I7%^!O^0A<_P#7(?SKM*\ZO\9UT_A"O-=<_P"0
MS>_]=37I5>;ZQSKUT#T\X_SJ\/NR:NQGX/I1M/3'-?._P_\ $VKW^N00>(]1
MN+;0_P"TM9&D3QW#%;Z\CN9E$%PW&WRXQF.+E6P3G*A:?\,=63Q5;^'[7QGK
MUU:::OA6QO+%I-2>T6[E=I!<S-*&4R.FV,8)^4'..<UZGL['%SGT+2[3TP<U
MY7X!\6:O>?#*"YUD7O\ 9Q@O=WB;S466.U22189S&1N9VB"ON"G.0>]<'#K!
MM_&#:"-=N!X/GU?3X[B[@U>2XA^SO:S,A:Z+;HWFD1-Z @#Y<'YJ7LWJ/F/H
M_!]**^?&UR]7P]X0U";Q;=6^G6_C%K"TCDND0:C9"Y=$DED8[I551M'.#P3G
MBOH/(/(Y':IE'E&I7"BBBH*"BBB@ HI&8*I9B%4#)8G  ]36?9>(M)U+'V/5
M;&[S((AY%RC_ #D$A>#UP#Q[&@#1HHHH **BCN89+B2W2:-[B,*TD*L"Z!ON
MDCJ,X./7%+;W$5W")8)4GB)($D;!E.#@\CT((_"@"2BBB@ HJ*.ZADN)8$FC
M>>(*9(E<%T#9VEAU&<'&>N*EH **** "BBB@ HHHH ***Y;XH_$/3OA1\/\
M6_%FJ O::; 9/)4X::0G"1CW9B!^M-)MV0MM3J&(2,NQ"(.K,< ?C47VZU_Y
M^K?_ +_+_C7XZ?%;X]^-OC)KDVH:_K5RMNS$P:9:RM':VZ]E5 >?J<DUP?VR
MY_Y^I_\ OZW^->BL&[:R.1XE=$?N/]NM?^?JW_[_ "_XT?;K7_GZM_\ O\O^
M-?AQ]LN?^?J?_OZW^-'VRY_Y^I_^_K?XT_J?][\!?6?(_<?[=:_\_5O_ -_E
M_P :/MUK_P _5O\ ]_E_QK\./MES_P _4_\ W];_ !H^V7/_ #]3_P#?UO\
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M<S['KUQ'X;U&" 7"Z+=PP1%XA+Y$B11X&2N>%7&WD<=*T5O[,M:HMW; W/\
MQ[KYR_OAC^#GYN/3->,:]\"[OQ WB/4_L>G:;J]]J6GWENEM( 1;P1()+3S=
MA"JSJ3]TJ2%)%5]0^#'B>2WT>ST]=.L[*UFBNR\\ZSW4,@O//D03&(':5^ZL
M>P E@<@BCECW#F?8]C\,^)++Q=H=OJVG&1K.=I%0RIL;*2-&V1_O(:U*YCX:
M^&KKP?X+L=)O6B:Y@DN'8PMN7$EQ)(N#_NN/QS73UD[7T+6P4444AG$_&;1=
M1\0?#O4+/3()+R4S6\L]E"VU[NW29'FA7D<O&&&,\YQWKEO$UCIWC;5?"">'
M]%U3188=?MI+R^M]+:P>*$03@$,R _+D G! W#!YKU^C)]:M2LK$N-SYX&L?
M$;^QQ]K?Q!'JD5@$T9;>UREW>+=RH?MF$P 8EA.6VJ59F!S6J@\86\T=[K6J
M>)H](NM:U&&^738M\UI;QE_L8A18R_EL>KX)("=!7N631DU7M/(GE\SYYTNZ
M\>PZK9W6N0:M86]TNE)K%]I=F#=^4([DG!1&.[=Y D"@[=QQ@$UF>#;;X@Z)
M9^'=-B?4=%TY(R]MYUG,Y>9KZ9I1<)'&W)C*<.47#$@YKZ9R:,FG[3R#D\SY
MYOO^%BVVDZ5>/JNN+'?76I?;=T3L]F4E=;)42&)G$97YB<$,=N2!6K#9^/-2
M\1P)>ZOKL%M-K,=E<-8QB&'[&=.$CRH"A*9N!C=G@DK7N.312]IY#Y?,^=M+
MU7QG%IMU=:IIFN#4M0M=)ADN[* V\@D6&?S&E=(G?:&" A5."P^Z":]E^&MW
MK%]\/_#MQX@22/7)+*,WJS)L<2X^;<O8UTF3ZT4I2YN@U&W4****S*"BBB@
MHHHH *^>/V^-(O-6_9IUEK-6=;.]M+NX5?\ GDLF&)]@6!KZ'JMJ6FVFM:;=
M:??V\=W8W4303V\HRDD;##*1Z$&KA+EDI=B9+F31^&M%?9GQ8_X)R>(;+6;B
M[^'NH6FI:/*Q>/3M2F\FXMP?X ^"K@=B<'UKS;_A@OXS?] "R_\ !E%_C7N1
MK4Y*_,>6Z4T[6/GRBOH/_A@SXS?] "R_\&47^-'_  P9\9O^@!9?^#*+_&G[
M6G_,A>SGV/GRBOH/_A@SXS?] "R_\&47^-'_  P9\9O^@!9?^#*+_&CVM/\
MF0>SGV/GRBOH/_A@SXS?] "R_P#!E%_C1_PP9\9O^@!9?^#*+_&CVM/^9![.
M?8^?**^@_P#A@SXS?] "R_\ !E%_C1_PP9\9O^@!9?\ @RB_QH]K3_F0>SGV
M/GRO3_V8-)O-:_:$\ 6]BK-,FJQ7#;?X8XSO<GVV@_G7>Z?^P#\8KVX6*72]
M+LD)YFN-23:/^^<G]*^R/V8/V2]+_9]AGU2]O$USQ==Q^5+?(A6*VC/)CA!Y
MY/5CR<8X%8U:\(Q=G=FE.E)R5T?0#<L3[U^3W[;FDWFD_M->+VO%8+>M!=V[
M-T>)H44$>P*L/PK]8*\6_:5_9CT7]H?1+8R7/]C^)=/5EL=45-PVGDQ2K_$A
M//'(/(]*\[#U%3G=[';6@YQLC\E:*^D-6_X)^_%_3[MXK>PTK4X@?EGM]055
M8>N' (^E4O\ A@SXS?\ 0 LO_!E%_C7K^UI_S(\_V<^Q\^45]!_\,&?&;_H
M67_@RB_QH_X8,^,W_0 LO_!E%_C1[6G_ #(7LY]CY\HKZ#_X8,^,W_0 LO\
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M '\'^%<I119 =7_PM;QC_P!#)?\ _?P?X4?\+6\8_P#0R7__ '\'^%<I119
M=7_PM;QC_P!#)?\ _?P?X4?\+6\8_P#0R7__ '\'^%<I119 =7_PM;QC_P!#
M)?\ _?P?X4?\+6\8_P#0R7__ '\'^%<I119 >B^&?CQXKT&\1[N];6+3/[RW
MNL$D?[+ 9!KZ>\-^(;/Q5H=IJM@Y>VN4W+NZJ>A4^X/%?#E?37[,S3'P+>B3
M/DB_;RL]/NKNQ^-95(JUT5%ZV/5[JZAL;6:YN)%B@A0R22-T50,DU\R>./V@
MM=UJ^ECT.=M(TU6Q&T:CSI!_>9CTSZ"O:?C6TR_"[7C!G=Y2AMO7;O7=^E?(
M%%.*W8Y-G5_\+6\8_P#0R7__ '\'^%=[\-_V@M2M=2@L?$TPO;&9@GVTJ!)"
M3P"V/O+Z]Q7B](WW3]*UY4R+L^]N#R#D=012UB>"6F;P;H1N,^>;*'=NZ_<'
M6MNN,W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#I/ W_(0N?^N0_G7:5Q?@;_D(7/\
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M7?&+_GGX<_\ !:?_ (NCZC6\@^M4S]4<T9K\KO\ AY=\8O\ GGX<_P#!:?\
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M !1110 4444 %%%% $-Y9VVHV_D7EM#=P=?+N(UD7\B#63_P@?AC_H6M&_\
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M ^RP_P#/)/\ OD4?98?^>2?]\BBBB[ /LL/_ #R3_OD4?98?^>2?]\BBBB[
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9YY)_WR***+L!T<,<9)1%4_[(Q3Z**0'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>picture2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 picture2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #S LL# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'SQ/X7\)VB^)=4TRXBO[?5+BPU*ZAN)IHY(=5%LD<JJV9 PF0*J[-NP G!W
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MY@-GYBO.[8E+>>P.U1C'WFR<?85 !1110 4444 %%%% !1110 4444 %%%%
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MM8I 9(&(! =>HR"*UJYW4O!&E7&O'Q);:?:0^*8K62UM]3:,[@K#A7VD;U!
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MH90>&) W=.<U\]Z/\!?&'AFQ\,7DV@W&M21^'O[%O--TWQ!_9TELRW$L@/F
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MIU1PW$5PT@BE20QML<(P.UNN#Z'D<5)0 44V21(8V>1E1%Y+,< 4Z@ HHHH
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M3DERI.Z>_1F\QC'R$)5@<JH]-A_:P\#:MJ-UI_A^'Q#XJU"T"O<VNCZ#=2/
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MRZ5^VA^T/\-;K1M7U3Q-?7UGJD'VRTM]=M8Y(;N .4++A58#<K#((/%?I/\
MLG_M3Z-^T]X+FO8+<:3XCTTK%JFDE]WE,1\LD9_BC;!P>H((/OK7P=2A'G>J
M\B*6)A5?*M&>YT445P'4%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "L/Q=X'\.^/M+.F^)=#T_7; G/V?4+9)D!]0&!P?<5N44T
MVG="WW/-O"?[-OPL\"ZHFI:#X!T#3=00Y2YBL4,B'U4D$C\*])HHIRE*6LG<
M%%1T2"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140096125346400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 25,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KIORA PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0443284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">332 Encinitas Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Encinitas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">224-9600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KPRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001372514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MY?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ <3AY6 =!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" !Q.'E8:"];O>X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " !Q.'E8F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( '$X>5@V
M!D+\6 0  !H1   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " !Q.'E8GZ ;\+$"  #B#   #0
M    @ &;#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( '$X>5B7BKL<P
M !,"   +              "  7</  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M '$X>5BJQ"(6,P$  "("   /              "  6 0  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " !Q.'E8)!Z;HJT   #X 0  &@
M@ ' $0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !Q
M.'E899!YDAD!  #/ P  $P              @ &E$@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"  #O$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="kprx-20240325.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="kprx-20240325.htm">kprx-20240325.htm</File>
    <File>kprx-20240325.xsd</File>
    <File>kprx-20240325_lab.xml</File>
    <File>kprx-20240325_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "kprx-20240325.htm": {
   "nsprefix": "kprx",
   "nsuri": "http://www.eyegatepharma.com/20240325",
   "dts": {
    "inline": {
     "local": [
      "kprx-20240325.htm"
     ]
    },
    "schema": {
     "local": [
      "kprx-20240325.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "kprx-20240325_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kprx-20240325_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.eyegatepharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20240325.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20240325.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001372514-24-000027-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001372514-24-000027-xbrl.zip
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MN;E!?W;TN?%B?VO&NR->]RM27&#!.P0A67&'K&$WDCVGR#5I$0 $'_IVA'&
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M%!A54,O:0]M=E_VD#G;KAJ>S42<D=YKQXK [XFCP[334)F[W0'?,3HN?JOS
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M87-E9&5C96UB97(N:'1M4$L! A0#%     @ <3AY6(N&8%!P#P  H60  !$
M             ( !?14  &MP<G@M,C R-# S,C4N:'1M4$L! A0#%     @
M<3AY6*JTPO)P @  ?P<  !$              ( !'"4  &MP<G@M,C R-# S
M,C4N>'-D4$L! A0#%     @ <3AY6 +RBV%%"@  %%@  !4
M ( !NR<  &MP<G@M,C R-# S,C5?;&%B+GAM;%!+ 0(4 Q0    ( '$X>5AI
MO91TV 8   (S   5              "  3,R  !K<')X+3(P,C0P,S(U7W!R
;92YX;6Q02P4&      4 !0!0 0  /CD

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>kprx-20240325_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="kprx-20240325.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2024-03-25</startDate>
            <endDate>2024-03-25</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001372514</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-03-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">KIORA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36672</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">98-0443284</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">332 Encinitas Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 102</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Encinitas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">92024</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">224-9600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">KPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
